Skip to content

Continuous Infusion of Palonosetron for Preventing of Postoperative Nausea and Vomiting

Effect of Continuous Infusion of Palonosetron Following Single Prophylactic Injection of Palonosetron for Preventing Postoperative Nausea and Vomiting

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01482468
Enrollment
132
Registered
2011-11-30
Start date
2012-03-31
Completion date
2012-07-31
Last updated
2012-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Nausea and Vomiting

Brief summary

The purpose of this study is to determine whether continuous infusion of palonosetron after its prophylactic single injection can further reduce the incidence of postoperative nausea and vomiting in patients undergoing gynecological laparoscopic surgery.

Interventions

DRUGcontinuous infusion of palonosetron added to prophylactic single injection of palonosetron

continuous infusion of palonosetron 0.00075 mg/hour after single injection of palonosetron 0.075mg

DRUGcontinuous infusion of normal saline added to prophylactic single injection of palonosetron

continuous infusion of normal saline after single injection of palonosetron 0.075mg

Sponsors

Incheon St.Mary's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* ASA Physical Status 1 or 2 * Elective gynaecological laparoscopic surgery of ≥ 1h duration

Exclusion criteria

* Anti-emetics, steroids, or psychoactive medications within 24 h of study initiation * Vomiting or retching in the 24 h preceding surgery * Cancer chemotherapy within 4 weeks or emetogenic radiotherapy within 8 weeks before study entry * Ongoing vomiting from gastrointestinal disease

Design outcomes

Primary

MeasureTime frame
incidence of postoperative nausea and vomiting24 hours after surgery

Secondary

MeasureTime frame
severity of nauseafor 24 hours after sugery

Countries

South Korea

Contacts

Primary ContactSoo Kyoung Park
hardmong@korea.com82-32-280-5410

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026